Replimune Group, Inc. (NASDAQ:REPL) Receives $19.29 Average Price Target from Analysts

Replimune Group, Inc. (NASDAQ:REPL) has been given an average recommendation of “Buy” by the eight brokerages that are presently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $19.29.

A number of research analysts have recently commented on the stock. HC Wainwright upped their price target on shares of Replimune Group from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Jefferies Financial Group increased their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. Finally, BMO Capital Markets increased their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd.

Replimune Group Trading Down 2.6 %

NASDAQ REPL opened at $13.61 on Thursday. The company’s 50-day moving average price is $12.71 and its 200-day moving average price is $11.92. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The stock has a market cap of $1.05 billion, a PE ratio of -4.43 and a beta of 1.30. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). Equities research analysts forecast that Replimune Group will post -2.97 earnings per share for the current year.

Insider Buying and Selling at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the sale, the chief executive officer now directly owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Hedge funds have recently modified their holdings of the company. Sterling Capital Management LLC lifted its position in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after buying an additional 1,655 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Replimune Group by 696.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after buying an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd lifted its position in shares of Replimune Group by 8,798.9% during the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after buying an additional 8,183 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Replimune Group during the fourth quarter valued at about $117,000. Finally, Quantinno Capital Management LP purchased a new stake in shares of Replimune Group during the fourth quarter valued at about $127,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.